GILD - Gilead Sciences, Inc. Annual Revenue Growth (Last Twelve Months)

Brandmark of Gilead Corp (GILD)

The relative year-over-year (LTM) revenue dynamics on the general GURU.Markets platform chart demonstrate the growth rates of Gilead Sciences, Inc. (GILD), where the 6.90 level captures the latest values. Gilead Sciences, Inc. (GILD) generates revenue from antiviral drugs and cellular oncology. Current growth offsets the decline in COVID-19 drug sales, although patent disputes necessitate R&D expenditures. Stagnation risks persist due to dependence on a narrow range of medications.

GILD (Gilead Sciences, Inc.) Sales Growth YoY (TTM) history from 02/11/2024 to 11/19/2026

Gilead Sciences Inc (GILD) - metric breakdowns and financial figures

Fundamental company valuation:Gilead Corp
Original product of Gilead

This indicator measures the rate of change in total revenue over the last twelve months, allowing for the identification of real operational business dynamics regardless of market speculation. An analysis of relative revenue growth over the last four quarters compared to the previous year for Gilead Sciences, Inc. (GILD) confirms the effectiveness of investments in a top-tier scientific staff, where steady sales expansion serves as the primary validation of the commercial success of innovative drug development.